Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results

被引：12
作者：
Pereyra-Rodriguez, J. J. [1 ,17 ]
Herranz, P. [2 ]
Figueras-Nart, I [3 ]
Perez, B. [4 ]
Elosua, M. [5 ]
Munera-Campos, M. [6 ]
Melgosa-Ramos, J. [7 ]
Zaragoza, V [8 ]
Silvestre, J. F. [9 ]
Campos-Dominguez, M. [10 ]
Guilabert, A. [11 ]
Miquel, J. [12 ]
Alcantara-Luna, S. [13 ]
de la Cueva, P. [14 ]
Serra-Baldrich, E. [15 ]
Armario-Hita, J. C. [16 ]
Rodriguez, Jose Juan Pereyra
机构：
[1] Univ Hosp Virgen Rocio, Dept Dermatol, Seville, Spain
[2] Univ Hosp La Paz, Dept Dermatol, Madrid, Spain
[3] Univ Hosp Bellvitge, Dept Dermatol, Barcelona, Spain
[4] Univ Hosp Ramon & Cajal, Dept Dermatol, Madrid, Spain
[5] Univ Hosp Puerta Hierro, Dept Dermatol, Madrid, Spain
[6] Univ Hosp Germans Trias i Pujol, Dept Dermatol, Badalona, Spain
[7] Univ Hosp Doctor Peset, Dept Dermatol, Valencia, Spain
[8] Univ Hosp Gen Valencia, Dept Dermatol, Valencia, Spain
[9] Univ Hosp Alicante, Dept Dermatol, Alicante, Spain
[10] Univ Hosp Gregorio Maranon, Dept Dermatol, Madrid, Spain
[11] Gen Hosp Granollers, Dept Dermatol, Barcelona, Spain
[12] Univ Hosp Arnau Vilanova, Dept Dermatol, Valencia, Spain
[13] Juan Ramon Jimenez Hosp, Dept Dermatol, Huelva, Spain
[14] Infanta Leonor Hosp, Dept Dermatol, Madrid, Spain
[15] St Pau Hosp, Dept Dermatol, Barcelona, Spain
[16] Univ Hosp Puerto Real, Dept Dermatol, Puerto Real, Spain
[17] Univ Hosp Virgen del Roci, Dept Dermatol, Avda Manuel Siurot S-N, Seville 41013, Spain
来源：
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY | 2023年 / 33卷 / 03期
关键词：
Atopic dermatitis; Atopic eczema; Upadacitinib; JAK-inhibitors; Real-world evidence; DOUBLE-BLIND; ADOLESCENTS; PLACEBO; ADULTS;
D O I：
10.18176/jiaci.0831
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：211 / 213
页数：3
相关论文
共 50 条
  • [21] Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
    Le, Michelle
    Berman-Rosa, Melissa
    Ghazawi, Feras M.
    Bourcier, Marc
    Fiorillo, Loretta
    Gooderham, Melinda
    Guenther, Lyn
    Hanna, Sameh
    Hong, H. Chih-Ho
    Landells, Ian
    Lansang, Perla
    Marcoux, Danielle
    Wiseman, Marni C.
    Yeung, Jensen
    Lynde, Charles
    Litvinov, Ivan V.
    FRONTIERS IN MEDICINE, 2021, 8
  • [22] Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis
    Batalla, Ana
    Suh-Oh, Hae Jin
    Hernandez, Gregorio Carretero
    Miquel-Miquel, Javier
    Botella-Estrada, Rafael
    Martorell-Calatayud, Antonio
    Sanz-Motilva, Virginia
    Figueras-Nart, Ignasi
    Florez, Angeles
    JEADV CLINICAL PRACTICE, 2023, 2 (03): : 571 - 575
  • [23] Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
    Hagino, Teppei
    Yoshida, Mai
    Hamada, Risa
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [24] Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis
    Chen, Qianyu
    Cui, Lian
    Chen, Zeyu
    Gao, Yunlu
    Shi, Yuling
    HELIYON, 2023, 9 (11)
  • [25] Upadacitinib and Dupilumab Demonstrate Superior Efficacy in the Treatment of Adolescent Atopic Dermatitis: A Network Meta-Analysis
    Zhao, Zuotao
    Peng, Chengyue
    Liu, Lijuan
    Zheng, Yaqi
    Tan, Yen
    Song, Xiaoting
    Zhang, Peixin
    Huang, Xiaojie
    Zhang, Litao
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2025,
  • [26] The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
    Napolitano, Maddalena
    Fabbrocini, Gabriella
    Ruggiero, Angelo
    Marino, Vincenzo
    Nocerino, Mariateresa
    Patruno, Cataldo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 1135 - 1147
  • [27] Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    ANNALS OF DERMATOLOGY, 2025, 37 (02) : 86 - 95
  • [28] Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results
    Silverberg, Jonathan, I
    Guttman-Yassky, Emma
    Simpson, Eric L.
    Papp, Kim A.
    Blauvelt, Andrew
    Chu, Chia-Yu
    Hong, H. Chih-ho
    Gold, Linda F. Stein
    Bieber, Thomas
    Kabashima, Kenji
    Rosmarin, David
    Gamelli, Amy
    Calimlim, Brian
    Vigna, Namita
    Hu, Xiaofei
    Yang, Yang
    Wu, Xiaoqiang
    Huang, Xiaohong
    Suravaram, Smitha
    Teixeira, Henrique D.
    Raymundo, Eliza
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II8 - II8
  • [29] Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
    Chiricozzi, Andrea
    Gori, Niccolo
    Narcisi, Alessandra
    Balato, Anna
    Gambardella, Alessio
    Ortoncelli, Michela
    Marzano, Angelo Valerio
    Balestri, Riccardo
    Palazzo, Giovanni
    Pellegrino, Michele
    Romanelli, Marco
    Tripepi, Giovanni
    Peris, Ketty
    Costanzo, Antonio
    DRUGS IN R&D, 2022, 22 (03) : 245 - 252
  • [30] Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, : 770 - 778
12345